| Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012 B Wu, K Bell, A Stanford, DM Kern, O Tunceli, S Vupputuri, I Kalsekar, ... BMJ Open Diabetes Research and Care 4 (1), e000154, 2016 | 196 | 2016 |
| Predictors of medication adherence in patients with type 2 diabetes mellitus SM Curkendall, N Thomas, KF Bell, PL Juneau, AJ Weiss Current medical research and opinion 29 (10), 1275-1286, 2013 | 168 | 2013 |
| The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data JL Meyers, S Parasuraman, KF Bell, JP Graham, SD Candrilli Archives of Public Health 72, 1-12, 2014 | 59 | 2014 |
| Economic burden of comorbid chronic kidney disease and diabetes RB McQueen, S Farahbakhshian, KF Bell, KV Nair, JJ Saseen Journal of medical economics 20 (6), 585-591, 2017 | 54 | 2017 |
| Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population ET Wittbrodt, JM Eudicone, KF Bell, DM Enhoffer, K Latham, JB Green Am J Manag Care 24 (8 Suppl), S138-45, 2018 | 47 | 2018 |
| Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population ET Wittbrodt, JM Eudicone, KF Bell, DM Enhoffer, K Latham, JB Green Am J Manag Care 24 (8), S146-S155, 2018 | 31 | 2018 |
| Comparing medication adherence and persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or sulfonylureas KF Bell, K Cappell, M Liang, AM Kong American Health & Drug Benefits 10 (4), 165, 2017 | 27 | 2017 |
| Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting A Chakravarty, M Rastogi, P Dhankhar, KF Bell Journal of Medical Economics 21 (5), 497-509, 2018 | 25 | 2018 |
| Medical care costs associated with long-term weight maintenance versus weight gain among patients with type 2 diabetes GA Nichols, K Bell, TM Kimes, M O’Keeffe-Rosetti Diabetes Care 39 (11), 1981-1986, 2016 | 25 | 2016 |
| Patient preferences for diabetes treatment attributes and drug classes EM Flood, KF Bell, MC de la Cruz, FM Ginchereau-Sowell Current medical research and opinion 33 (2), 261-268, 2017 | 21 | 2017 |
| Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007-2012. BMJ Open Diabetes Res Care 2016; 4: e000154 B Wu, K Bell, A Stanford, DM Kern, O Tunceli, S Vupputuri Epub 2016/04/26, 2016 | 15 | 2016 |
| Economic implications of weight change in patients with type 2 diabetes mellitus. K Bell, S Parasuraman, M Shah, A Raju, J Graham, L Lamerato, ... The American journal of managed care 20 (8), e320-9, 2014 | 15 | 2014 |
| Association between weight change, clinical outcomes, and health care costs in patients with type 2 diabetes J Mukherjee, C Sternhufvud, N Smith, K Bell, M Stott-Miller, D McMorrow, ... Journal of managed care & specialty pharmacy 22 (5), 449-466, 2016 | 12 | 2016 |
| Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption SS Johnston, K Bell, J Gdovin, Y Jing, J Graham Hospital Practice 40 (1), 15-23, 2012 | 10 | 2012 |
| INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus … AR Hansen, TS Stanton, MH Hong, EEW Cohen, HM Mehanna, ... Journal of Clinical Oncology 38 (15_suppl), TPS6591-TPS6591, 2020 | 9 | 2020 |
| Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two … KF Bell, A Katz, JJ Sheehan Risk Management and Healthcare Policy, 231-241, 2016 | 9 | 2016 |
| A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes H Huang, KF Bell, R Gani, CW Tugwell, JM Eudicone, MR Krukas-Hampel Am J Manag Care 24 (8 Suppl), S132-S137, 2018 | 8 | 2018 |
| Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population K Bell, S Parasuraman, A Raju, M Shah, J Graham, M Denno Journal of managed care & specialty pharmacy 21 (3), 220-228, 2015 | 7 | 2015 |
| Clinical outcomes associated with rates of sulfonylurea use among physicians K Bognar, KF Bell, D Lakdawalla, A Shrestha, JT Snider, N Thomas, ... Am J Manag Care 19, 16-221, 2013 | 4 | 2013 |
| Economic burden of moderate chronic kidney disease in type 2 diabetes RB McQueen, S Farahbakhshian, K Bell, K Nair, J Saseen Value in Health 19 (3), A14, 2016 | 3 | 2016 |
Ozgur TunceliPrincipal Scientist, Carelon ResearchVerified email at carelon.com
